Engineering “Healthy Weight Loss” to Redefine Metabolic Quality via Precision Antibody-Peptide Conjugates (APCs) to Prevent Sarcopenia
- Utilizing an Activin IIA/B bispecific antibody to lift the “biological brake” on muscle growth, addressing the critical limitation of current GLP-1s where up to 40% of weight loss is derived from lean muscle mass
- Matching the fat-loss potency of high-dose injectables while simultaneously driving muscle hypertrophy, offering a “best-in-class” body composition profile that accelerates adipose-specific weight loss and boosts basal energy expenditure
- Optimizing the pharmacokinetic profile of lead candidate SPX-001 and its GLP-1 conjugates to ensure stable, monthly dosing that preserves metabolic fitness, prevents weight regain “rebound,” and provides a durable foundation for long-term cardiometabolic health